Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 23,985 |
|
|||||
| News | - | ||||||
| Day High | 4.8966 | Low High |
|||||
| Day Low | 4.405 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Moleculin Biotech Inc | MBRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.3218 | 7.47% | 4.63 | 16:02:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.50 | 4.405 | 4.8966 | 4.63 | 4.3082 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 445 | 23,985 | $ 4.67 | $ 111,973 | - | 4.28 - 15.75 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:15:05 | 50 | $ 4.7992 | USD |
Moleculin Biotech Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 154.7M | 33.41M | - | 0 | -29.77M | -0.89 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Moleculin Biotech News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MBRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.59 | 4.8966 | 4.28 | 4.40 | 12,945 | 0.04 | 0.87% |
| 1 Month | 5.79 | 6.09 | 4.28 | 4.92 | 24,765 | -1.16 | -20.03% |
| 3 Months | 7.5615 | 10.35 | 4.28 | 7.15 | 113,153 | -2.93 | -38.77% |
| 6 Months | 7.335 | 15.75 | 4.28 | 8.61 | 149,234 | -2.71 | -36.88% |
| 1 Year | 10.80 | 15.75 | 4.28 | 8.86 | 153,256 | -6.17 | -57.13% |
| 3 Years | 52.2345 | 59.85 | 4.28 | 24.65 | 162,271 | -47.60 | -91.14% |
| 5 Years | 20.55 | 131.70 | 4.28 | 26.71 | 965,870 | -15.92 | -77.47% |
Moleculin Biotech Description
| Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member. |
